Clinical trials: Pulmonary Artery Hypertension
Hypertension, Pulmonary
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life…
- Trial name
- CAPTURE (NCT02545465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH
The development of disease-targeted medication for the treatment of pulmonary arterial hypertension (PAH) has significantly improved within the last years, leading to the development of 10 approved agents.
- Trial name
- EPIC (NCT02484807)
- Testing
- no intervention, only observation of different groups
- Where
- Germany
- Volunteers
- 125 people
- Sponsor
- Heidelberg University
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise
The study aim is to monitor, during exercise tests carried out in various conditions, the alveolar dead space, by means of continuous transcutaneous measurement of Pt CO2, which would be used as a surrogate for arterial PaCO2.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Chronic Heart Failure, Pulmonary Arterial Hypertension
- Trial name
- TEASE (NCT03718780)
- Testing
- simultaneous determination of PaCO2 and PtCO2, Hyperventilation test, Exercise test
- Where
- 4 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Metropole Savoie
Interstitial Lung Disease, COPD
Pulmonary Hypertension SOLAR
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI).
- Conditions
- Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
- Trial name
- PH SOLAR (NCT04778046)
- Testing
- Hyperpolarized 129Xe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bastiaan Driehuys
Pulmonary Hypertension
Relation Between Mean Pulmonary Artery Pressure and Pulmonary Acceleration Time and Comparison With Previous Formulae
Since the pulmonary artery hypertension is defined based on MPAP and the two previous formulae relating MPAP and PAT were derived in western population, the investigator planned to conduct a prospective study to derive a new…
- Trial name
- NCT03013062
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pulmonary Arterial Hypertension (PAH)
AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?
Pulmonary Arterial Hypertension is a rare and progressive condition that compromises pulmonary circulation and can lead to right ventricular failure.
- Trial name
- AIRDROP (NCT07457762)
- Testing
- The patients will receive guidance on inhaler use and adherence
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs.
- Trial name
- LIGHTRAY (NCT06664801)
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 98 sites in United States, Argentina and 19 more
- Volunteers
- 164 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Validation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary Hypertension
In this study the diagnostic accuracy of a diagnostic tool for the diagnosis of post-capillary pulmonary hypertension will be investigated.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- Optiek 2-0 (NCT06405126)
- Testing
- Optiek predictive model
- Where
- 4 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- KU Leuven
Pulmonary Arterial Hypertension
Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension (PAH)
- Trial name
- RELIEF-PAH (NCT03789643)
- Testing
- JTT-251
- Sponsor
- Shionogi Inc.
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Pulmonary Arterial Hypertension
ACT-293987 in Pulmonary Arterial Hypertension
Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
- Trial name
- NCT01112306
- Testing
- ACT-293987
- Where
- 157 sites in United States, Argentina and 36 more
- Volunteers
- 709 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
The primary objective of this study is to assess the safety and tolerance of changing patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
- Trial name
- SCOBA-PH (NCT01330108)
- Testing
- ambrisentan
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Hypertension, Pulmonary
Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular affection, which treatment has evolved in the last few years, improving quality of life. However, adherence to treatment has not been assessed in such patients.
- Trial name
- ETHAP (NCT01038284)
- Testing
- Patient education, Data collection
- Where
- 11 sites in France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Grenoble
Pulmonary Arterial Hypertension
Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)
The purpose of this clinical study is to assess the safety of PLX-PAD to treat pulmonary arterial hypertension (PAH). PLX-PAD is a cell-based product made of allogeneic Mesenchymal-like Adherent Stromal Cells (ASCs), derived from…
- Trial name
- NCT01795950
- Testing
- PLX-PAD
- Where
- 2 sites in Australia
- Volunteers
- 6 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH)
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
- Trial name
- (STOP-PAH) (NCT06872112)
- Testing
- Artesunate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Joseph C. Wu
Pulmonary Artery Hypertension
Training With Whole Body Vibration Device in Patients With PAH
Title of study / project: Influence of training with whole body vibration device on Quality of Life (QoL), exercise capacity, as well as on the effects of muscle power and muscle function in patients with pulmonal arterial…
- Trial name
- GALILEO-PAH (NCT01763112)
- Testing
- Exercise Group Galileo PAH
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Klinikum der Universität Köln
Atrial Fibrillation, Hypertension, Pulmonary
Safety Procedure Pulmonary Artery Denervation in Addition to Pulmonary Vein Isolation Combined With Ganglionated Plexi Ablation in Patients With Persistent Atrial Fibrillation and Pulmonary Hypertension
Some patients with a long history of AF develops PH "reactive" type with an increase in pulmonary vascular resistance due to vasoconstriction or structural changes of the vascular wall.
- Conditions
- Atrial Fibrillation, Hypertension, Pulmonary, Heart Diseases, Arrhythmias, Cardiac
- Trial name
- NCT02298244
- Testing
- PV isolation + GP Ablation, PV isolation + GP ablation + Pulmonary GP ablation
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Krasnoyarsk Regional Hospital
Pulmonary Arterial Hypertension
The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI
Explore the impact of drug candidate CS1 on pathological vascular remodeling of small pulmonary arteries in the disease pulmonary arterial hypertension (PAH).
- Trial name
- NCT06907693
- Testing
- CT Pulmonary Angiography Scan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Prisma Health-Upstate
Group 2 Pulmonary Hypertension, Heart Failure
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
This early feasibility study is intended to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension
- Trial name
- PreVail-PH2 (NCT06052072)
- Testing
- Gradient Denervation System
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gradient Denervation Technologies
Asthma, Atrial Fibrillation
Improving Quality by Maintaining Accurate Problems in the EHR
The overall goal of the IQ-MAPLE project is to improve the quality of care provided to patients with several heart, lung and blood conditions by facilitating more accurate and complete problem list documentation.
- Conditions
- Asthma, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease
- Trial name
- IQ-MAPLE (NCT02596087)
- Testing
- Problem List Suggestion
- Where
- 4 sites in United States
- Volunteers
- 2,386 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital